Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Creekmore

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
AWHONN Lifelines|July 30, 1999
Stopping a silent killer. Preventing heart disease in womenJ Kuehn, P McMahon, S Creekmore
The American Journal of Physiology|December 1, 1984
Hypertension after ending captopril administration: pathogenesis in 2-kidney, 1-clip ratJ M DeForrest, J S Creekmore, R A Ferrone
Intensive & Critical Care Nursing|September 1, 1994
Effect of level of lung injury on HR, MAP and SaO2 changes during suctioningM J Grap, C Glass, M Corley, et al.
The American Journal of Cardiology|April 21, 1982
Angiotensin II is a necessary component for the development of hypertension in the two kidney, one clip ratJ M DeForrest, R C Knappenberger, M J Antonaccio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1988
Effects of interleukin-2 immunotherapy on renal functionG A Kozeny, J D Nicolas, S Creekmore, et al.
Cancer Research|November 15, 1990
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimenJ W Clark, J W Smith, R G Steis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanomaJ P Dutcher, S Creekmore, G R Weiss, et al.
Cancer Research|May 15, 1990
Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamineW J Urba, L C Hartmann, D L Longo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphomaR A Messmann, E S Vitetta, D Headlee, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
AWHONN Lifelines|July 30, 1999
Stopping a silent killer. Preventing heart disease in womenJ Kuehn, P McMahon, S Creekmore
The American Journal of Physiology|December 1, 1984
Hypertension after ending captopril administration: pathogenesis in 2-kidney, 1-clip ratJ M DeForrest, J S Creekmore, R A Ferrone
Intensive & Critical Care Nursing|September 1, 1994
Effect of level of lung injury on HR, MAP and SaO2 changes during suctioningM J Grap, C Glass, M Corley, et al.
The American Journal of Cardiology|April 21, 1982
Angiotensin II is a necessary component for the development of hypertension in the two kidney, one clip ratJ M DeForrest, R C Knappenberger, M J Antonaccio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1988
Effects of interleukin-2 immunotherapy on renal functionG A Kozeny, J D Nicolas, S Creekmore, et al.
Cancer Research|November 15, 1990
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimenJ W Clark, J W Smith, R G Steis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanomaJ P Dutcher, S Creekmore, G R Weiss, et al.
Cancer Research|May 15, 1990
Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamineW J Urba, L C Hartmann, D L Longo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphomaR A Messmann, E S Vitetta, D Headlee, et al.
Pageof 1